TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9141006

Group type: EXPERIMENTAL
Intervention: Bromocriptine (given intramuscularly)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (conventional immunosuppression only)
Number of subjects: 45
Study: 7967344

Group type: EXPERIMENTAL
Intervention: Ultralow sodium dialysate (USD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal sodium dialysate (NSD)
Number of subjects: 10
Study: 3303815

Group type: EXPERIMENTAL
Intervention: Clindamycin and primary resuture
Number of subjects: 35

Group type: COMPARATOR
Intervention: Not resutured but spontaneously healed
Number of subjects: 35
Study: 31538418

Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery (GKS)
Number of subjects: 264
Study: 29455501

Group type: EXPERIMENTAL
Intervention: Core strength training group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional rehabilitation training group
Number of subjects: 80
Study: 25467826

Group type: COMPARATOR
Intervention: 10-day standard sequential therapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: levofloxacin-containing sequential therapy
Number of subjects: 200
Study: 23420705

Group type: EXPERIMENTAL
Intervention: 3D-rotational angiography
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard angiography
Number of subjects: 80
Study: 22024610

Group type: COMPARATOR
Intervention: Hydrated (HY)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dehydrated (DHY)
Number of subjects: 14
Study: 18647131

Group type: EXPERIMENTAL
Intervention: Comprehensive smoking cessation intervention including preoperative computerized counseling, tailored self-help material, brief advice from clinical staff, NRT, telephone counseling, and post-discharge support from a Quitline.
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care control group.
Number of subjects: 118
Study: 16938120

Group type: EXPERIMENTAL
Intervention: Patient self-management (PSM) of anticoagulation therapy
Number of subjects: 617

Group type: COMPARATOR
Intervention: Routine clinic-based care
Number of subjects: 617
Study: 11823669

Group type: EXPERIMENTAL
Intervention: Structured speed‐dependent treadmill training (STT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Limited progressive treadmill training (LTT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional gait training (CGT)
Number of subjects: 60
Study: 9950107

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (625 mg every 8 hours for 10 days)
Number of subjects: 100
Study: 7567310

Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg daily for 10 days)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (40 mg/kg/day given every 8 hours for 10 days)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 296

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 296
Study: 2142611

Group type: EXPERIMENTAL
Intervention: Mini Wright peak flow meter
Number of subjects: 212

Group type: COMPARATOR
Intervention: Turbine spirometer
Number of subjects: 212
Study: 6996138

Group type: EXPERIMENTAL
Intervention: Standardized senna tablets (Senokot; Reckitt & Colman)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 29173985

Group type: EXPERIMENTAL
Intervention: 8-week resistance training program focused on lower limbs
Number of subjects: 46
Study: 27125669

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m2 as a 2- to 5-min intravenous infusion on days 1 and 8 of each 21-day cycle
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Number of subjects: 51
Study: 24336820

Group type: EXPERIMENTAL
Intervention: Daily co-trimoxazole (CMX) 800 mg/160 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine intermittent preventive treatment (IPT-SP)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Daily co-trimoxazole (CMX)
Number of subjects: 264
Study: 22119661

Group type: EXPERIMENTAL
Intervention: Auditory alpha activity training (8-12Hz)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Random beta training
Number of subjects: 50

Group type: COMPARATOR
Intervention: No training at all
Number of subjects: 50
Study: 20452749

Group type: EXPERIMENTAL
Intervention: Psychosocial treatment
Number of subjects: 74
Study: 18035081

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 3122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3122
Study: 16129801

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 12017952

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with fentanyl citrate plus bupivacaine using a low flow elastomerics infuser
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intermittent epidural analgesia with bupivacaine plus intravenous Ketorolaco
Number of subjects: 50
Study: 10419117

Group type: EXPERIMENTAL
Intervention: High palmitic acid intake (16:0) with high 18:2n-6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High palmitic acid intake (16:0) with low 18:2n-6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low palmitic acid intake (16:0) with high 18:2n-6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low palmitic acid intake (16:0) with low 18:2n-6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High palmitic acid intake (16:0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low palmitic acid intake (16:0)
Number of subjects: 0
Study: 7492381

Group type: EXPERIMENTAL
Intervention: GM‐CSF 5 micrograms/kg per day (n = 11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (n = 9)
Number of subjects: 20
Study: 2255573

Group type: EXPERIMENTAL
Intervention: Group A (formula with predominantly 18:2 omega-6)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group B (balanced mix of 18:2 omega-6 and 18:3 omega-3)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group C (formula with essential fatty acids and supplemented with marine oil for 22:6 omega-3)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Human milk-fed group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 32
Study: 6993548

Group type: EXPERIMENTAL
Intervention: Bromocriptine (CB-154)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Double dose of CB-154 (5 mg po) one hour before arginine test
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31740867

Group type: EXPERIMENTAL
Intervention: Two-point fixation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Three-point fixation
Number of subjects: 60
Study: 28049477

Group type: EXPERIMENTAL
Intervention: Bͻkͻͻ net fan systems (one fan per member)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Water filters
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study: 27872117

Group type: EXPERIMENTAL
Intervention: Standard care (neoadjuvant long course radiotherapy ± chemotherapy and APER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: APER surgery alone
Number of subjects: 0
Study: 24560173

Group type: EXPERIMENTAL
Intervention: DFDBA plus lincomycin therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: DFDBA alone (Control)
Number of subjects: 20
Study: 22133470

Group type: EXPERIMENTAL
Intervention: Beta-blocker up-titration to 12.5% of target dose
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Beta-blocker up-titration to 25% of target dose
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Beta-blocker up-titration to 50% of target dose
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Beta-blocker up-titration to 100% of target dose
Number of subjects: 302

Group type: COMPARATOR
Intervention: Groups 3/4 (50% and 100% target dose)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Groups 1/2 (12.5% and 25% target dose)
Number of subjects: 302
Study: 19295389

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 61
Study: 17959943

Group type: EXPERIMENTAL
Intervention: Greek tsatsiki with 4.2 g raw garlic (verum)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Greek tsatsiki without garlic (placebo)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Daily ingestion of 4.2 g of raw garlic over 1 week
Number of subjects: 18
Study: 16296439

Group type: EXPERIMENTAL
Intervention: One‐Step (one‐bottle bonding agent)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer (glutaraldehyde‐based agent)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 40
Study: 11983432

Group type: EXPERIMENTAL
Intervention: Global phase shift (PS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local event onset shift (EOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perturbation magnitude up to +/‐15% of the sequence period (500 milliseconds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger perturbations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized design and two additional task contexts
Number of subjects: 0
Study: 10217550

Group type: EXPERIMENTAL
Intervention: 21 mg/day transdermal nicotine patch (Nicoderm CQ)
Number of subjects: 56
Study: 1322118

Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Interactional group psychotherapy
Number of subjects: 79
Study: 6381610

Group type: EXPERIMENTAL
Intervention: HuIFN‐alpha 2 nasal drops (9 X 10(6) international units, three times a day for five days)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: HuIFN‐alpha 2 nasal spray (9 X 10(6) international units, three times a day for five days)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2
Study: 30848783

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 110
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Hospitalization (any reason)
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Cardiovascular hospitalization
Number of subjects: 18113
Study: 29801943

Group type: EXPERIMENTAL
Intervention: Brief interventions (BIs) without a specific topic in police custody settings
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Four strategies for engaging in BIs
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Determinants of success of the intervention
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Engagement in BIs
Number of subjects: 2000
Study: 27220276

Group type: EXPERIMENTAL
Intervention: Web-based brief motivational intervention
Number of subjects: 1449

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 1449
Study: 25920294

Group type: EXPERIMENTAL
Intervention: Clinical Practice Guideline (CPG) compliance group
Number of subjects: 600

Group type: COMPARATOR
Intervention: Clinical Practice Guideline (CPG) non-compliance group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Both groups (CPG-compliant and non-compliant)
Number of subjects: 600
Study: 23622801

Group type: COMPARATOR
Intervention: 14-day quadruple therapy (OMAB group) comprising omeprazole 20mg, metronidazole 500 mg, amoxicillin 1g, and bismuth subcitrate 240 mg
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 14-day triple regimen (OCP group) comprising omeprazole 20mg plus clarithromycin 500 mg and penbactam 750 mg
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 14-day triple regimen (OCA group) comprising omeprazole 20mg plus clarithromycin 500 mg and amoxicillin 1g
Number of subjects: 330
Study: 21227000

Group type: EXPERIMENTAL
Intervention: Normal-sized Gateway(™) balloon and Wingspan(™) stent
Number of subjects: 72

Group type: COMPARATOR
Intervention: Undersized Gateway(™) balloon and Wingspan(™) stent
Number of subjects: 72
Study: 18665788

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Estrogen (E) plus progestin (P)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 16803495

Group type: EXPERIMENTAL
Intervention: Radical hysterectomy with or without adjuvant radiotherapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 94
Study: 12869883

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 28 days
Number of subjects: 208

Group type: COMPARATOR
Intervention: Nizatidine 150 mg twice daily for 28 days
Number of subjects: 208
Study: 10968855

Group type: EXPERIMENTAL
Intervention: Guidewire sphincterotome (GS) without guidewire
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 9271971

Group type: EXPERIMENTAL
Intervention: One-to-one nurse support
Number of subjects: 413

Group type: COMPARATOR
Intervention: Usual intrapartum nursing care
Number of subjects: 413
Study: 8285627

Group type: EXPERIMENTAL
Intervention: Ceftriaxone at 2 g/day for 3 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Chloramphenicol at 50 mg/kg of body weight per day for 14 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ceftriaxone and Chloramphenicol
Number of subjects: 29
Study: 3556591

Group type: EXPERIMENTAL
Intervention: Adjuvant testosterone
Number of subjects: 155

Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 155
Study: 29745059

Group type: EXPERIMENTAL
Intervention: Withdrawal of TNFi treatment
Number of subjects: 817

Group type: COMPARATOR
Intervention: Continuation of TNFi treatment
Number of subjects: 817
Study: 27791207

Group type: EXPERIMENTAL
Intervention: Virtual Reality Reflection Therapy (VRRT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 25
Study: 24919526

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 814
Study: 22805297

Group type: EXPERIMENTAL
Intervention: QRS fragmentation (fQRS) identified in inferior leads
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: QRS fragmentation (fQRS) in patients with LBBB
Number of subjects: 1040
Study: 20467596

Group type: EXPERIMENTAL
Intervention: Connective tissue grafts
Number of subjects: 10

Group type: COMPARATOR
Intervention: No augmentation (Control)
Number of subjects: 10
Study: 18946891

Group type: EXPERIMENTAL
Intervention: Standard follow-up program in the heart failure clinic (HFC)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: NT-proBNP monitoring in the heart failure clinic (HFC)
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Treatment in general practice
Number of subjects: 1250
Study: 16393726

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 88 microg bid
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 220 microg bid
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 440 microg bid
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (all doses)
Number of subjects: 397
Study: 12791224

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10687572

Group type: EXPERIMENTAL
Intervention: Partogram with action line at 2 hours
Number of subjects: 615

Group type: COMPARATOR
Intervention: Partogram with action line at 3 hours
Number of subjects: 615

Group type: COMPARATOR
Intervention: Partogram with action line at 4 hours
Number of subjects: 615
Study: 8728487

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) administered at 1300 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) administered at 1800 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 0
Study: 1794818

Group type: EXPERIMENTAL
Intervention: Sezolamide 1.8% twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 36
Study: 6837251

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg perorally the night before operation and diazepam 0.2 mg per kg body weight perorally at 7.00 a.m. on the day of operation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg perorally the night before operation and morphine/scopolamine i.m. 1 h prior to operation
Number of subjects: 62

Group type: COMPARATOR
Intervention: No flunitrazepam given on the night before operation, morphine/scopolamine i.m. 1 h preoperatively
Number of subjects: 62
Study: 29992486

Group type: EXPERIMENTAL
Intervention: Combined exercise plus diet program (12-week, weekly aerobic exercise, 1200 kcal/day diet)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined exercise plus diet program
Number of subjects: 32
Study: 29851107

Group type: EXPERIMENTAL
Intervention: FMT-S (single faecal infusion via colonoscopy followed by a 14-day vancomycin course)
Number of subjects: 56

Group type: COMPARATOR
Intervention: FMT-M (multiple faecal infusions plus a 14-day vancomycin course)
Number of subjects: 56
Study: 29231361

Group type: EXPERIMENTAL
Intervention: Combined therapy of ginger-isolated moxibustion and escitalopram (10 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Escitalopram (10 mg/day)
Number of subjects: 80
Study: 24899589

Group type: EXPERIMENTAL
Intervention: Sub-xyphoid pleural drain (Group SI)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intercostal pleural drain (Group II)
Number of subjects: 68
Study: 22435319

Group type: EXPERIMENTAL
Intervention: 0.05% CPC mouthwash
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo mouthwash without CPC
Number of subjects: 60
Study: 19665644

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 258

Group type: COMPARATOR
Intervention: Sulfasalazine and hydroxychloroquine
Number of subjects: 258
Study: 17417658

Group type: EXPERIMENTAL
Intervention: Live-attenuated varicella zoster vaccine
Number of subjects: 40
Study: 15196111

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36
Study: 11772824

Group type: EXPERIMENTAL
Intervention: 0.075% ropivacaine with fentanyl 2 microg/mL
Number of subjects: 59

Group type: COMPARATOR
Intervention: 0.075% bupivacaine with fentanyl 2 microg/mL
Number of subjects: 59
Study: 11477910

Group type: EXPERIMENTAL
Intervention: Prepared Rehmannia polysaccharide (PRP) associated with stanozolol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Stanozolol alone (Control)
Number of subjects: 34
Study: 8597777

Group type: EXPERIMENTAL
Intervention: Monopharmacy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 200
Study: 2540788

Group type: EXPERIMENTAL
Intervention: Four courses of cytotoxic chemotherapy (cyclophosphamide, vincristine, etoposide)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Eight courses of cytotoxic chemotherapy (cyclophosphamide, vincristine, etoposide)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Four courses of chemotherapy followed by relapse chemotherapy (methotrexate and doxorubicin)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Eight courses of chemotherapy followed by relapse chemotherapy (methotrexate and doxorubicin)
Number of subjects: 610
Study: 1078711

Group type: EXPERIMENTAL
Intervention: Surgical treatment (coronary bypass)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medical treatment (control)
Number of subjects: 72
Study: 31960079

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 0
Study: 31039587

Group type: EXPERIMENTAL
Intervention: Elastic wrapping (30 mm Hg) during dangling
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unwrapped dangling
Number of subjects: 30
Study: 28177719

Group type: EXPERIMENTAL
Intervention: Polyphenol beverage (1-1.5 L/day, approximately 400 mg of gallic acid equivalents per day)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo beverage (without polyphenol enrichment)
Number of subjects: 277
Study: 25116481

Group type: EXPERIMENTAL
Intervention: BMS-820836 (0.5 mg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: BMS-820836 (0.1-4 mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 22915051

Group type: EXPERIMENTAL
Intervention: 100 mL PS yoghurt drink consumed 45 min prior to a solid meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mL PS yoghurt drink consumed during a solid meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mL PS yoghurt drink consumed 45 min after a solid meal
Number of subjects: 12
Study: 21569487

Group type: EXPERIMENTAL
Intervention: Cleansing product (CP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 100
Study: 19229417

Group type: EXPERIMENTAL
Intervention: Pulmonary veins isolation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Modified Cox‐maze procedure
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (isolated mitral valve surgery)
Number of subjects: 42
Study: 17135035

Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg/day and norethisterone acetate 1 mg/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 14561021

Group type: EXPERIMENTAL
Intervention: IV/PO moxifloxacin 400 mg QD
Number of subjects: 376

Group type: COMPARATOR
Intervention: IV/PO amoxicillin clavulanate 1200/625 mg TID +/- IV/PO clarithromycin 500 mg BID
Number of subjects: 376
Study: 10908248

Group type: EXPERIMENTAL
Intervention: Thrombolysis within 2 hours
Number of subjects: 2770

Group type: EXPERIMENTAL
Intervention: Thrombolysis within 2-4 hours
Number of subjects: 2770

Group type: EXPERIMENTAL
Intervention: Thrombolysis within 4-6 hours
Number of subjects: 2770

Group type: EXPERIMENTAL
Intervention: Thrombolysis within 6 hours
Number of subjects: 2770